Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 1 |
| Since 2017 (last 10 years) | 1 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Attention Deficit… | 1 |
| Comorbidity | 1 |
| Compliance (Psychology) | 1 |
| Drug Abuse | 1 |
| Drug Therapy | 1 |
| Marijuana | 1 |
| Outcomes of Treatment | 1 |
| Pilot Projects | 1 |
| Randomized Controlled Trials | 1 |
| Sample Size | 1 |
| Stimulants | 1 |
| More ▼ | |
Author
| Amy L. Mahony | 1 |
| C. Jean Choi | 1 |
| Cale Basaraba | 1 |
| Christina A. Brezing | 1 |
| Daniel J. Brooks | 1 |
| Frances R. Levin | 1 |
| John J. Mariani | 1 |
| Martina Pavlicova | 1 |
| Nasir Naqvi | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
| New York | 1 |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkFrances R. Levin; John J. Mariani; Martina Pavlicova; C. Jean Choi; Cale Basaraba; Amy L. Mahony; Daniel J. Brooks; Christina A. Brezing; Nasir Naqvi – Journal of Attention Disorders, 2024
Objective: To determine if treatment of co-occurring adult ADHD and Cannabis Use Disorder (CUD) with extended-release mixed amphetamine salts (MAS-ER) would be effective at improving ADHD symptoms and promoting abstinence. Method: A 12-week randomized, double-blind, two-arm pilot feasibility trial of adults with comorbid ADHD and CUD (n = 28)…
Descriptors: Comorbidity, Attention Deficit Hyperactivity Disorder, Marijuana, Drug Abuse
